Johnson & Johnson’s (NYSE: JNJ) pharma arm, Janssen, has announced interim data from the Phase IIIb STARDUST study of Stelara (ustekinumab).
In the trial, people received an intravenous (IV) dose followed by a subcutaneous (SC) dose.
The data show that, at week 16, 79% of people with moderately to severely active Crohn’s disease (CD) achieved clinical response and 67% were in clinical remission.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze